Page 3 - Skye Bioscience News Today

Skye Bioscience, Inc. , a pharmaceutical company developing drugs targeting the endocannabinoid system to address diseases including glaucoma and metabolic conditions, will present an overview of its...

Skye Bioscience, Inc. , a pharmaceutical company developing drugs targeting the endocannabinoid system, initially through modulation of the CB1 receptor, to address diseases including glaucoma and...

Skye Bioscience, Inc. , a pharmaceutical company developing drugs targeting the endocannabinoid system, initially through modulation of the CB1 receptor, to address diseases including glaucoma and...

Skye Bioscience, Inc. , a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, with...

Shares of Skye Bioscience, Inc. (OTCMKTS:SKYE – Get Free Report) reached a new 52-week low during trading on Wednesday . The stock traded as low as $2.01 and last traded at $2.45, with a volume of 2497 shares changing hands. The stock had previously closed at $2.35. Skye Bioscience Stock Performance The firm’s fifty day […]

A recent California district court addressed the question of whether, for insurance coverage purposes, a SOX whistleblower claim is a “securities claim,” and answered that question in...

Skye Bioscience, Inc. (OTCMKTS:SKYE – Get Free Report) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 73,800 shares, a growth of 63.6% from the July 31st total of 45,100 shares. Based on an average daily trading volume, of 2,428,000 shares, the days-to-cover […]

Skye Bioscience, Inc. (OTCMKTS:SKYE – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 73,800 shares, a growth of 63.6% from the July 31st total of 45,100 shares. Based on an average daily volume of 2,428,000 shares, […]

Staying well-informed about a companys news releases and updates is paramount in the world of trading. These announcements often hold the key to understanding a companys performance, growth...

Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid system ("ECS").